Mainz Biomed Shareholders Approve All Proposals at EGM

TL;DR

Mainz Biomed EGM: All proposals passed. Shareholders are on board.

AI Summary

Mainz Biomed N.V. held an Extraordinary General Meeting of Shareholders on November 13, 2024, where all proposed resolutions were approved by the holders of ordinary shares. The minutes detailing these results are attached to this 6-K filing.

Why It Matters

Shareholder approval of all proposals at the Extraordinary General Meeting indicates alignment between management and investors on the company's direction.

Risk Assessment

Risk Level: low — This filing is a routine report of an approved shareholder meeting and does not introduce new financial or operational risks.

Key Players & Entities

• Mainz Biomed N.V. (company) — Registrant
• November 13, 2024 (date) — Date of Extraordinary General Meeting

FAQ

Filing Documents

• ea0221368-6k_mainz.htm (6-K) — 17KB
• ea022136801ex99-1_mainz.htm (EX-99.1) — 64KB
• ex99-1_001.jpg (GRAPHIC) — 13KB
• ex99-1_002.jpg (GRAPHIC) — 26KB
• ex99-1_003.jpg (GRAPHIC) — 55KB
• 0001213900-24-099203.txt ( ) — 212KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F Other Events Results of Extraordinary General Meeting of Shareholders On November 13, 2024, Mainz Biomed N.V. (the “Company”) held an Extraordinary General Meeting of Shareholders (the “Extraordinary General Meeting”). All proposals brought before the holders of the Company’s ordinary shares at such meeting were approved. Minutes announcing the results of the Extraordinary General Meeting are attached hereto as Exhibit 99.1.The final results of each of the agenda items submitted to a vote by the shareholders are as follows: At the Extraordinary General Meeting, a total of 9,803,128 shares (or 16.83%) of the Company’s issued and outstanding shares of record held as of October 16, 2024, the record date for the Extraordinary General Meeting, were present either in person or by proxy. At the Extraordinary General Meeting, the following proposals were voted on and approved: 1. To authorize the amendment to the articles of association of the Company to effect a reverse stock split: Votes For Votes Against Abstentions 8,262,897 1,507,091 33,140 This current report on Form 6-K and the exhibit hereto are hereby incorporated by reference into our registration statement on Form F-3 (no. 333-269091) as well as our registration statement on Form S-8 (no. 333-273203). Exhibit No. Exhibit 99.1 Board Minutes Regarding the Extraordinary General Meeting dated November 13, 2024 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 15, 2024 By: /s/ William J. Caragol Name: William J. Caragol Title Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR